“Countering all the positive outcomes of buprenorphine treatment for patients with addiction are the negatives of the drug’s misuse that are frequently cited by critics, including legislators who oppose expanded use of pharmacotherapies to treat addiction. Saturday’s ASAM Policy Plenary opened the door to a passionate discussion of how to address the problem.
The session, “Consequence of Changing the Buprenorphine Prescribing Limit,” featured H. Westley Clark, MD, JD, MPH, CAS, FASAM, reviewing facts about buprenorphine use and misuse. Then, he and session moderators Scott A. Teitelbaum, MD, FAAP, FASAM, and Mark Kraus, MD, FASAM, opened the floor to discussion from attendees, but the session ended with about a dozen people still lined up at microphones waiting to speak.
Opinions ranged from those supporting physicians being allowed to prescribe buprenorphine beyond the 100-patient limit, to those who questioned a need for that expansion, to suggestions for other options. Two themes often cited by speakers were to remember the patients and to remember what caused concerns about drug misuse.”
Source: American Society of Addiction Medicine – April 26, 2015